^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | glecirasib (JAB-21822) (KRAS G12C inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Excerpt:
...Advanced (metastatic or unresectable) KRAS G12C mutant solid tumors, with failure or absence of standard treatment 3....
Trial ID:
Source:
Title:
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
Excerpt:
...- Histologically or cytologically confirmed solid tumors with KRAS G12C mutation...
Trial ID:
More C2 evidence
Source:
Title:
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
Excerpt:
...Pathologically documented, locally-advanced or metastatic NSCLC with KRAS p.G12C mutation identified through molecular testing....
Trial ID:
Less C2 evidence
Source:
Title:
Jacobio's KRAS G12C Inhibitor JAB-21822 was Granted Breakthrough Therapy Designations by China CDE
Published date:
12/15/2022
Excerpt:
Jacobio Pharma (1167. HK) announced that the Company’s in-house KRAS G12C inhibitor JAB-21822 was granted breakthrough therapy designations for the second line and above treatment of advanced or metastatic non-small cell lung cancer (NSCLC) patients with KRAS G12C mutation by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA). The designation was granted based on the solid clinical efficacy and safety data of JAB-21822....The preliminary phase I clinical data...shows that as of April 1, 2022, a total of 72 patients with advanced solid tumors were enrolled, and efficacy was assessed for 32 NSCLC patients with KRAS G12C mutation. The overall response rate (ORR) was 56.3% (18/32) and the disease control rate (DCR) was 90.6% (29/32).
